but Novo Nordisk is trying to change that. The Danish drugmaker has reported the first phase 3 results with its new basal insulin product – insulin icodec – which backs up earlier data ...

For the current quarter, Novo Nordisk is expected to post earnings of $0.93 per share, indicating a change of +12.1% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.3% over ...

In a phase 3 trial spanning 68 weeks, Novo Nordisk tested the drug’s efficacy compared to a placebo. The trial included 1,206 people who have a mean baseline body weight of about 225 pounds ...